Brian Elsbernd - 26 Nov 2024 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Chief Compliance/Legal Officer
Signature
/s/ Brian Elsbernd
Issuer symbol
CPRX
Transactions as of
26 Nov 2024
Net transactions value
-$46,104
Form type
4
Filing time
29 Nov 2024, 20:08:45 UTC
Previous filing
25 Nov 2024
Next filing
11 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common Stock, par value $0.001 per share Options Exercise $201,478 +50,244 +40% $4.01 174,677 26 Nov 2024 Direct
transaction CPRX Common Stock, par value $0.001 per share Sale $201,345 -9,300 -5.3% $21.65 165,377 26 Nov 2024 Direct F1
transaction CPRX Common Stock, par value $0.001 per share Options Exercise $39,122 +9,756 +5.9% $4.01 175,133 26 Nov 2024 Direct
transaction CPRX Common Stock, par value $0.001 per share Sale $85,359 -3,956 -2.3% $21.58 171,177 26 Nov 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to Purchase Common Stock Options Exercise $0 -50,244 -4.4% $0.000000 1,104,766 26 Nov 2024 Common Stock 50,244 $4.01 Direct F2
transaction CPRX Options to Purchase Common Stock Options Exercise $0 -9,756 -0.88% $0.000000 1,095,010 26 Nov 2024 Common Stock 9,756 $4.01 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold for tax purposes and to pay the exercise price of the options and not as a result of a disagreement with the Company. Mr. Elsbernd remains an executive officer of the Company.
F2 Options vested in three annual tranches beginning on January 2, 2019.